Breaking News

ICON Implements Informatica MDM

By Kristin Brooks | March 6, 2014

Integration software aims to improve access to business-critical data

ICON plc has selected Informatica Corp. to improve its clinical trials and development process by implementing the multi-domain Informatica MDM solution, which creates a consolidated view of business-critical data, such as investigators and sites, and the relationships between the data. This strategy aims to improve the potential of ICON's data for faster, better-informed decisions, including clinical trial planning, trial execution services and improved reporting.

Andrew Thompson, vice president of technology, ICON, said, "Our business is all about data. Informatica unlocks the potential of ICON's data, delivering 360-degree insights into, study and site related program activities. This enables the company to continuously monitor the clinical trials process, optimize operations based on real-time alerts and data insights and mitigate risk. The ultimate outcome is increased productivity."

Dennis Moore, senior vice president and general manager of MDM at Informatica says, "In today's hyper-competitive and rapidly evolving healthcare market, accurate information and effective drug discovery and clinical trials are the lifeblood of life sciences companies. To succeed, life sciences organizations need an enterprise view of compound research across current and previous trials. Informatica MDM delivers that single, 360-degree view of the clinical trials program, enabling companies like ICON to increase efficiency and reduce costs."

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important